Literature DB >> 16838068

Phytosphingosine stimulates the differentiation of human keratinocytes and inhibits TPA-induced inflammatory epidermal hyperplasia in hairless mouse skin.

Sujong Kim1, Il Hong, Jung Sun Hwang, Jin Kyu Choi, Ho Sik Rho, Duck Hee Kim, Ihseop Chang, Seung Hun Lee, Mi-Ock Lee, Jae Sung Hwang.   

Abstract

The binding of sphingoid bases to peroxisome proliferator-activated receptor (PPAR) has been detected in a solid-phase binding assay. However, sphingoid base-induced changes in PPAR transactivation activity have not been examined. In this report, we show by reporter gene analyses that phytosphingosine (PS), a natural sphingoid base, activates the transcriptional activity of PPARs in the immortalized human keratinocyte, HaCaT. Real-time PCR analyses showed that the mRNA level of PPARgamma was increased after PS treatment in HaCaT cells in a dose- and time-dependent manner. Because PPARs play important roles in skin barrier homeostasis by regulating epidermal cell growth, terminal differentiation, and inflammatory response, we examined the effect of PS on normal human epidermal keratinocytes (NHEKs) and mouse skin. PS increased the production of cornified envelope in NHEKs by approximately 1.8-fold compared with controls. Epidermal differentiation marker proteins such as involucrin, loricrin, and keratin1 were also increased in PS-treated NHEKs, by ELISA or Western blotting analysis. A [(3)H]thymidine incorporation assay showed that PS inhibited DNA synthesis in NHEKs to 20% compared with controls. The antiproliferative and anti-inflammatory effects of PS were examined in a mouse model of irritant contact dermatitis produced by topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA). PS blocked epidermal thickening and edema and the infiltration of inflammatory cells into the dermis in the skin of TPA-treated hairless mice. The anti-inflammatory effects of PS were confirmed by the observation that PS blocked the TPA-induced generation of prostaglandin E(2) in peripheral mononuclear leukocytes. Taken together, our results provide an insight into the multiple regulatory roles of PS in epidermal homeostasis, and furthermore point to the potential use of PS as a therapeutic agent in the treatment of inflammatory and proliferative cutaneous diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16838068      PMCID: PMC1514555          DOI: 10.2119/2006-00001.Kim

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  39 in total

1.  Fetal epidermal differentiation and barrier development In vivo is accelerated by nuclear hormone receptor activators.

Authors:  K Hanley; L G Kömüves; N M Bass; S S He; Y Jiang; D Crumrine; R Appel; M Friedman; J Bettencourt; K Min; P M Elias; M L Williams; K R Feingold
Journal:  J Invest Dermatol       Date:  1999-11       Impact factor: 8.551

2.  Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.

Authors:  Mingyue Li; Tak W Lee; Tony S K Mok; Timothy D Warner; Anthony P C Yim; George G Chen
Journal:  J Cell Biochem       Date:  2005-11-01       Impact factor: 4.429

3.  Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo.

Authors:  L G Kömüves; K Hanley; A M Lefebvre; M Q Man; D C Ng; D D Bikle; M L Williams; P M Elias; J Auwerx; K R Feingold
Journal:  J Invest Dermatol       Date:  2000-09       Impact factor: 8.551

4.  Endogenous nitric oxide activates prostaglandin F2 alpha production in human microglial cells but not in astrocytes: a study of interactions between eicosanoids, nitric oxide, and superoxide anion (O2-) regulatory pathways.

Authors:  N Janabi; S Chabrier; M Tardieu
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

5.  Ceramide composition of the psoriatic scale.

Authors:  S Motta; M Monti; S Sesana; R Caputo; S Carelli; R Ghidoni
Journal:  Biochim Biophys Acta       Date:  1993-09-08

6.  Keratinocyte differentiation is induced by cell-permeant ceramides and its proliferation is promoted by sphingosine.

Authors:  H Wakita; Y Tokura; H Yagi; K Nishimura; F Furukawa; M Takigawa
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

7.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.

Authors:  S A Kliewer; B M Forman; B Blumberg; E S Ong; U Borgmeyer; D J Mangelsdorf; K Umesono; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

8.  Lysophosphatidic acid induction of transforming growth factors alpha and beta: modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin.

Authors:  G A Piazza; J L Ritter; C A Baracka
Journal:  Exp Cell Res       Date:  1995-01       Impact factor: 3.905

9.  Evidence for separate control mechanisms at the message, protein, and enzyme activation levels for transglutaminase during calcium-induced differentiation of normal and transformed human keratinocytes.

Authors:  D F Gibson; A V Ratnam; D D Bikle
Journal:  J Invest Dermatol       Date:  1996-01       Impact factor: 8.551

10.  Coordinate changes in gene expression which mark the spinous to granular cell transition in epidermis are regulated by protein kinase C.

Authors:  A A Dlugosz; S H Yuspa
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

View more
  16 in total

1.  Phytosphingosine derivatives ameliorate skin inflammation by inhibiting NF-κB and JAK/STAT signaling in keratinocytes and mice.

Authors:  Byung-Hak Kim; Ji Min Lee; Yong-Gyu Jung; Sanghee Kim; Tae-Yoon Kim
Journal:  J Invest Dermatol       Date:  2013-10-31       Impact factor: 8.551

2.  Dietary glucosylceramide enhances cornified envelope formation via transglutaminase expression and involucrin production.

Authors:  Tatsuya Hasegawa; Haruo Shimada; Taro Uchiyama; Osamu Ueda; Masaya Nakashima; Yasuhiro Matsuoka
Journal:  Lipids       Date:  2011-03-17       Impact factor: 1.880

3.  Sphingosine 1-phosphate protects primary human keratinocytes from apoptosis via nitric oxide formation through the receptor subtype S1P₃.

Authors:  Elisabeth I Schmitz; Henrik Potteck; Melanie Schüppel; Marianti Manggau; Elly Wahydin; Burkhard Kleuser
Journal:  Mol Cell Biochem       Date:  2012-08-17       Impact factor: 3.396

4.  Preparation of (13)C-labeled ceramide by acetic acid bacteria and its incorporation in mice.

Authors:  Hiroyuki Fukami; Hideki Tachimoto; Mikiya Kishi; Takayuki Kaga; Hatsue Waki; Machiko Iwamoto; Yasukazu Tanaka
Journal:  J Lipid Res       Date:  2010-07-23       Impact factor: 5.922

Review 5.  Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate.

Authors:  Cungui Mao; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2008-06-13

6.  Sphingoid bases are taken up by Escherichia coli and Staphylococcus aureus and induce ultrastructural damage.

Authors:  C L Fischer; K S Walters; D R Drake; D R Blanchette; D V Dawson; K A Brogden; P W Wertz
Journal:  Skin Pharmacol Physiol       Date:  2012-10-30       Impact factor: 3.479

7.  Identification of Compounds with Potential Therapeutic Uses from Sweet Pepper (Capsicum annuum L.) Fruits and Their Modulation by Nitric Oxide (NO).

Authors:  Lucía Guevara; María Ángeles Domínguez-Anaya; Alba Ortigosa; Salvador González-Gordo; Caridad Díaz; Francisca Vicente; Francisco J Corpas; José Pérez Del Palacio; José M Palma
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

8.  4,8-Sphingadienine and 4-hydroxy-8-sphingenine activate ceramide production in the skin.

Authors:  Yoshiyuki Shirakura; Kanako Kikuchi; Kenji Matsumura; Katsuyuki Mukai; Susumu Mitsutake; Yasuyuki Igarashi
Journal:  Lipids Health Dis       Date:  2012-08-31       Impact factor: 3.876

Review 9.  Ceramides in Skin Health and Disease: An Update.

Authors:  Yoshikazu Uchida; Kyungho Park
Journal:  Am J Clin Dermatol       Date:  2021-07-20       Impact factor: 7.403

10.  Serum proteomic, peptidomic and metabolomic profiles in myasthenia gravis patients during treatment with Qiangji Jianli Fang.

Authors:  Chunmei Wang; Yonghai Lu; Zhixi Chen; Xiaobin Liu; Huangquan Lin; Hui Zhao; Jinyan Chen; Yiuwa Kwan; Saiming Ngai
Journal:  Chin Med       Date:  2012-07-28       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.